Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Cost effectiveness analysis of a next generation risk assessment score for cardiovascular disease.

Hytopoulos E, Lee ML, Beggs M, French C, Tong KB.

J Med Econ. 2014 Feb;17(2):132-41. doi: 10.3111/13696998.2013.869500. Epub 2013 Dec 12.

PMID:
24329735
2.

Clinical utility of a novel coronary heart disease risk-assessment test to further classify intermediate-risk patients.

Solomon MD, Tirupsur A, Hytopoulos E, Beggs M, Harrington DS, French C, Quertermous T.

Clin Cardiol. 2013 Oct;36(10):621-7. doi: 10.1002/clc.22185. Epub 2013 Aug 8.

3.

Analytical performance validation of a coronary heart disease risk assessment multi-analyte proteomic test.

Nolan N, Tee L, Vijayakumar S, Burazor I, Hytopoulos E, Biggs WH 3rd, Beggs M, French C, Harrington DS.

Expert Opin Med Diagn. 2013 Mar;7(2):127-36. doi: 10.1517/17530059.2013.753055. Epub 2012 Dec 11.

PMID:
23530883
4.

Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts.

Cross DS, McCarty CA, Hytopoulos E, Beggs M, Nolan N, Harrington DS, Hastie T, Tibshirani R, Tracy RP, Psaty BM, McClelland R, Tsao PS, Quertermous T.

Curr Med Res Opin. 2012 Nov;28(11):1819-30. doi: 10.1185/03007995.2012.742878.

5.

Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study.

Iribarren C, Phelps BH, Darbinian JA, McCluskey ER, Quesenberry CP, Hytopoulos E, Vogelman JH, Orentreich N.

BMC Cardiovasc Disord. 2011 Jun 14;11:31. doi: 10.1186/1471-2261-11-31.

6.

Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease.

Ardigo D, Assimes TL, Fortmann SP, Go AS, Hlatky M, Hytopoulos E, Iribarren C, Tsao PS, Tabibiazar R, Quertermous T; ADVANCE Investigators.

Physiol Genomics. 2007 Nov 14;31(3):402-9. Epub 2007 Aug 14.

PMID:
17698927
7.

Biological complexity and drug discovery: a practical systems biology approach.

Berg EL, Kunkel EJ, Hytopoulos E.

Syst Biol (Stevenage). 2005 Dec;152(4):201-6.

PMID:
16986261
8.

Characterization of compound mechanisms and secondary activities by BioMAP analysis.

Berg EL, Kunkel EJ, Hytopoulos E, Plavec I.

J Pharmacol Toxicol Methods. 2006 Jan-Feb;53(1):67-74. Epub 2005 Aug 11.

PMID:
16040258
9.

Approaches to the analysis of cell signaling networks and their application in drug discovery.

Berg EL, Hytopoulos E, Plavec I, Kunkel EJ.

Curr Opin Drug Discov Devel. 2005 Jan;8(1):107-14. Review.

PMID:
15679178
10.

Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models.

Kunkel EJ, Plavec I, Nguyen D, Melrose J, Rosler ES, Kao LT, Wang Y, Hytopoulos E, Bishop AC, Bateman R, Shokat KM, Butcher EC, Berg EL.

Assay Drug Dev Technol. 2004 Aug;2(4):431-41.

PMID:
15357924
11.

An integrative biology approach for analysis of drug action in models of human vascular inflammation.

Kunkel EJ, Dea M, Ebens A, Hytopoulos E, Melrose J, Nguyen D, Ota KS, Plavec I, Wang Y, Watson SR, Butcher EC, Berg EL.

FASEB J. 2004 Aug;18(11):1279-81. Epub 2004 Jun 18.

PMID:
15208272
12.

Method for analyzing signaling networks in complex cellular systems.

Plavec I, Sirenko O, Privat S, Wang Y, Dajee M, Melrose J, Nakao B, Hytopoulos E, Berg EL, Butcher EC.

Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1223-8. Epub 2004 Jan 26.

Supplemental Content

Loading ...
Support Center